Literature DB >> 18704546

The development of systemic sclerosis in a female patient with multiple sclerosis following beta interferon treatment.

A Powell1, M L Myles, E Yacyshyn.   

Abstract

We describe a 38-year-old patient with relapsing remitting multiple sclerosis who subsequently develops systemic sclerosis following a course of interferon B-1a injections. This rare association between MS and systemic sclerosis is interesting due to the added factor of beta interferon therapy prior to the onset of the systemic sclerosis. It is also important, as more patients are treated with interferon B-1a for multiple sclerosis, this is a potential association.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18704546     DOI: 10.1007/s10067-008-0972-3

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  8 in total

Review 1.  Multiple sclerosis in the course of systemic sclerosis.

Authors:  E Chroni; C Paschalis; T Stergiou; C Vlahanastasi; A P Andonopoulos
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

2.  Systemic sclerosis after interferon-alfa therapy for myeloproliferative disorders.

Authors:  L Beretta; M Caronni; M Vanoli; R Scorza
Journal:  Br J Dermatol       Date:  2002-08       Impact factor: 9.302

3.  Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States.

Authors:  R C Lawrence; C G Helmick; F C Arnett; R A Deyo; D T Felson; E H Giannini; S P Heyse; R Hirsch; M C Hochberg; G G Hunder; M H Liang; S R Pillemer; V D Steen; F Wolfe
Journal:  Arthritis Rheum       Date:  1998-05

4.  Interferon-gamma in the treatment of systemic sclerosis: a randomized controlled multicentre trial.

Authors:  A Grassegger; G Schuler; G Hessenberger; B Walder-Hantich; J Jabkowski; W MacHeiner; W Salmhofer; B Zahel; G Pinter; M Herold; G Klein; P O Fritsch
Journal:  Br J Dermatol       Date:  1998-10       Impact factor: 9.302

5.  Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-alpha 2b.

Authors:  S Singhal; R Powles; J Treleaven; J Mehta
Journal:  Bone Marrow Transplant       Date:  1997-06       Impact factor: 5.483

Review 6.  Immunopathogenesis of multiple sclerosis: the role of T cells.

Authors:  G Martino; H P Hartung
Journal:  Curr Opin Neurol       Date:  1999-06       Impact factor: 5.710

7.  Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial.

Authors:  C M Black; A J Silman; A I Herrick; C P Denton; H Wilson; J Newman; L Pompon; X Shi-Wen
Journal:  Arthritis Rheum       Date:  1999-02

8.  Systemic sclerosis developing in association with the use of interferon alpha therapy for chronic viral hepatitis.

Authors:  R Solans; J A Bosch; I Esteban; M Vilardell
Journal:  Clin Exp Rheumatol       Date:  2004 Sep-Oct       Impact factor: 4.473

  8 in total
  5 in total

Review 1.  Immunogenicity and other problems associated with the use of biopharmaceuticals.

Authors:  Michael G Tovey; Christophe Lallemand
Journal:  Ther Adv Drug Saf       Date:  2011-06

Review 2.  Toll-like receptors in mediating pathogenesis in systemic sclerosis.

Authors:  L Frasca; R Lande
Journal:  Clin Exp Immunol       Date:  2020-02-21       Impact factor: 4.330

3.  Differential DNA Methylation Landscape in Skin Fibroblasts from African Americans with Systemic Sclerosis.

Authors:  DeAnna Baker Frost; Willian da Silveira; E Starr Hazard; Ilia Atanelishvili; Robert C Wilson; Jonathan Flume; Kayleigh L Day; James C Oates; Galina S Bogatkevich; Carol Feghali-Bostwick; Gary Hardiman; Paula S Ramos
Journal:  Genes (Basel)       Date:  2021-01-20       Impact factor: 4.096

Review 4.  The Role of Cutaneous Type I IFNs in Autoimmune and Autoinflammatory Diseases.

Authors:  Jessica L Turnier; J Michelle Kahlenberg
Journal:  J Immunol       Date:  2020-12-01       Impact factor: 5.422

Review 5.  Safety, Tolerability, and Immunogenicity of Interferons.

Authors:  Michael G Tovey; Christophe Lallemand
Journal:  Pharmaceuticals (Basel)       Date:  2010-04-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.